EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Price:
16.75 USD
3.65%
Market Closed
Updated:
Apr 29, 2024
EyePoint Pharmaceuticals Inc
Cash from Financing Activities
|
EyePoint Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Cash from Financing Activities
$187.1m
|
CAGR 3-Years
71%
|
CAGR 5-Years
18%
|
CAGR 10-Years
32%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$15.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$9.4B
|
CAGR 3-Years
-101%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$4.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
18%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is EyePoint Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
187.1m
USD
187.1m
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Cash from Financing Activities amounts to 187.1m USD.
What is EyePoint Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
32%
32%
The average annual Cash from Financing Activities growth rates for EyePoint Pharmaceuticals Inc have been 71% over the past three years , 18% over the past five years , and 32% over the past ten years .
You don't have any saved screeners yet
